Lapatinib (GW-572016) Ditosylate

For research use only.

Catalog No.S1028

79 publications

Lapatinib (GW-572016) Ditosylate Chemical Structure

CAS No. 388082-77-7

Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 147 In stock
USD 257 In stock
USD 400 In stock
USD 670 In stock
USD 797 In stock
USD 1190 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Lapatinib (GW-572016) Ditosylate has been cited by 79 publications

Purity & Quality Control

Choose Selective HER2 Inhibitors

Biological Activity

Description Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Targets
ErbB2 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
ErbB4 [1]
(Cell-free assay)
9.2 nM 10.8 nM 367 nM
In vitro

Lapatinib Ditosylate weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib Ditosylate significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib Ditosylate inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib Ditosylate displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib Ditosylate potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HN5 cell line NYrm[4NHWHKxbHnm[ZJifGmxbjDhd5NigQ>? MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxtKGyrbnWsJGlEPTB;MD6wNlUh|ryP MmnhNVY1QDN5N{K=
BT474 cell line NFP0dldRem:uaX\ldoF1cW:wIHHzd4F6 MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGxibHnu[UwhUUN3ME2wMlAzPSEQvF2= NVzYT5E{OTZ2OEO3O|I>
HN5 cell MoHwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33lfmlvcGmkaYTpc44hd2ZiSF61JINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czygTWM2OD1yLkGyJO69VQ>? MlvrNVY4Pzd2MUC=
BT474 cell MkT5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13rV2lvcGmkaYTpc44hd2ZiQmS0O|Qh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNFgh|ryP NF3obFMyPjd5N{SxNC=>
N87 cell Mn\hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXM[2FNUW6qaXLpeIlwdiCxZjDOPFch[2WubDDndo94fGhiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNFgh|ryP MYCxOlc4PzRzMB?=
HFF cell M1fCfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1e0XGlvcGmkaYTpc44hd2ZiSF\GJINmdGxiZ4Lve5RpNCCLQ{WwQVkvQSEQvF2= NUfmdG9HOTZ5N{e0NVA>
SKBR3 cells MUHDfZRwfG:6aXPpeJkh[XO|YYm= MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFE4KM7:TR?= MYKxPVAzQDR{NR?=
A431 cells NXPNe49uS3m2b4TvfIlkcXS7IHHzd4F6 NWC1SoxNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOTB2IN88US=> NF3HTFMyQTh6OEe2NS=>
SKBR3 cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFI6KM7:TR?= M3jyTVE6QDh6N{[x
HepG2 cells NYjT[ow3WHKxbHnm[ZJifGmxbjDhd5NigQ>? M2jJVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwQVYvOjdizszN NVjwem1[OjBzNEO3O|g>
Hep3B2 cells NEOwW5lRem:uaX\ldoF1cW:wIHHzd4F6 M2SxPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwN2IzKGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NF02NjR7IN88US=> Mmf0NlAyPDN5N{i=
SKHEP1 cells MWPQdo9tcW[ncnH0bY9vKGG|c3H5 MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONSFXQNUBk\WyuczDh[pRmeiCqcoOgZpkhSVSSIHPvcpRmdnRiYYPzZZktKEmFNUC9OU4{KM7:TR?= NW\BfZM4OjBzNEO3O|g>
MCF7 cells M1jvPHBzd2yrZnXyZZRqd25iYYPzZZk> MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhcHK|IHL5JGFVWCClb370[Y51KGG|c3H5MEBKSzVyPU[uOkDPxE1? MnHVNlAyPDN5N{i=
MDA-MB-231 cells MlzBVJJwdGmoZYLheIlwdiCjc4PhfS=> NXjMUHNvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKGi{czDifUBCXFBiY3;ueIVvfCCjc4PhfUwhUUN3ME21MlQh|ryP MkfaNlAyPDN5N{i=
SK-BR-3 cells M3j2c3Bzd2yrZnXyZZRqd25iYYPzZZk> M2TaSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utRnIuOyClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVA:OC5yNDFOwG0> M1\TZ|IxOTR|N{e4
A431 cells MonvSpVv[3Srb36gZZN{[Xl? M{Dm[GlvcGmkaYTpc44hd2ZiRVfGVkBqdnS{YXPlcIx2dGG{IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNEOxJINmdGy|IHL5JGVNUVODLDDJR|UxRTBwMEWyJO69VQ>? NWDXcVU{OjB|NE[2OVU>
N87 cells MVTGeY5kfGmxbjDhd5NigQ>? NFrycWxKdmirYnn0bY9vKG:oIFXyZmIzKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF64O{Bk\WyuczDifUBGVEmVQTygTWM2OD1yLkGg{txO NGOwXYozODN2Nk[1OS=>
MIAPaCa cells MU\GeY5kfGmxbjDhd5NigQ>? NXrLS5h7UW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOUUGSYVPhJINmdGy|IHL5JGVNUVODLDDJR|UxRTBwNEOzJO69VQ>? NV2wdpB6OjB6MUe1NlM>
MIAPaCa cells M2jXRWZ2dmO2aX;uJIF{e2G7 MoTKTY5pcWKrdHnvckBw\iCHUlLiNkBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUWlCWGGFYTDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjF2IN88US=> MUGyNFgyPzV{Mx?=
CAL27 cells NG\XSFdEgXSxdH;4bYNqfHliYYPzZZk> NFq0doJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW|c3nu[{BGT0[UIHL5JJJme2G8dYLpckBlgWVicnXkeYN1cW:wIHHzd4F6NCCLQ{WwQVAvODB5IN88UU4> NXT6So9FOjFyOEC2Nlk>
SKOV3 cells MYnDfZRwfG:6aXPpeJkh[XO|YYm= M3vOVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z|IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhGWjJiYomgdoV{[Xq3cnnuJIR6\SC{ZXT1Z5Rqd25iYYPzZZktKEmFNUC9NE4xODNizszNMi=> NUC5VlhVOjFyOEC2Nlk>
CAL27 cells M3ftUmZ2dmO2aX;uJIF{e2G7 MYixOkBp MYPJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGNCVDJ5IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGVITlJiYX\0[ZIhOTZiaILzJIJ6KFenc4Tldo4h[myxdDygTWM2OD1yLkCzNkDPxE1? M2nCZlIyODhyNkK5
SK-BR-3 cells NUPR[Yk{WHKxbHnm[ZJifGmxbjDhd5NigQ>? NYDOTY51SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGemKEMjDveoVz\XiycnXzd4lv\yCqdX3hckBUUy2EUj2zJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA{OiEQvF2= M1PNVVIyPTdyOESz
BXF T24 cells NH34R3hEgXSxdH;4bYNqfHliYYPzZZk> M4\BbFQh\GG7cx?= Mo\DR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRnhHKFR{NDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9PU43PSEQvF2= MkXkNlIyPjl4MEG=
CXF 269L cells NYTJe2gyS3m2b4TvfIlkcXS7IHHzd4F6 NYjIcmEyPCCmYYnz MkjPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR3hHKDJ4OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVgvOzZizszN NYjpRWg3OjJzNkm2NFE>
DIFI cells NYPndIFES3m2b4TvfIlkcXS7IHHzd4F6 MoDSOEBl[Xm| M2LjZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRKTkliY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUCuNlM2KM7:TR?= NYTjfZpqOjJzNkm2NFE>
HT-29 cells MVvDfZRwfG:6aXPpeJkh[XO|YYm= MV20JIRigXN? NVPiWYliS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVQvPjJizszN Mo\xNlIyPjl4MEG=
RKO cells MY\DfZRwfG:6aXPpeJkh[XO|YYm= NGLDZ|E1KGSjeYO= MojIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVmtQKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD13LkO1JO69VQ>? MWqyNlE3QTZyMR?=
GXF251L cells NFPkO3BEgXSxdH;4bYNqfHliYYPzZZk> M4OxWFQh\GG7cx?= NFmxVm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIYEZ{NUHMJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yNjR6IN88US=> M3zrclIzOTZ7NkCx
LIXF 575L cells NXi1c2ltS3m2b4TvfIlkcXS7IHHzd4F6 MYq0JIRigXN? MlLrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUGlZTiB3N{XMJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF04NjF6IN88US=> M2jOcFIzOTZ7NkCx
LXFA 289L cells NWLEblNVS3m2b4TvfIlkcXS7IHHzd4F6 MkOyOEBl[Xm| NXrGfIU2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiIQTCyPFlNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD13Lke5JO69VQ>? MYmyNlE3QTZyMR?=
LXFA 526L MWXDfZRwfG:6aXPpeJkh[XO|YYm= NVHyb5lvPCCmYYnz M3jSTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNUK2UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:PC5{MTFOwG0> NFqyS3czOjF4OU[wNS=>
LXFA 629L cells M1fOPWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2TYd|Qh\GG7cx?= M2nOSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNkK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi56NzFOwG0> Mn3uNlIyPjl4MEG=
LXFL 1121L cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= M2HQcVQh\GG7cx?= NF\zT25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[OIEGxNlFNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD15LkezJO69VQ>? MYKyNlE3QTZyMR?=
LXFL 529L cells NIDyZ|VEgXSxdH;4bYNqfHliYYPzZZk> M4LmclQh\GG7cx?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZNKDV{OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVMvPTFizszN M1K5XFIzOTZ7NkCx
MCF7 cells M1yzUmN6fG:2b4jpZ4l1gSCjc4PhfS=> MYq0JIRigXN? MkPiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;ND64N{DPxE1? NIPSNWEzOjF4OU[wNS=>
MDA231 cells M4\DdWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2G2dlQh\GG7cx?= MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEzOzFiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUeuO{DPxE1? MWiyNlE3QTZyMR?=
OVXF 899L MV7DfZRwfG:6aXPpeJkh[XO|YYm= MYe0JIRigXN? MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWnhHKDh7OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVMvOzVizszN MUiyNlE3QTZyMR?=
PAXF 546L cells NUe1bYFqS3m2b4TvfIlkcXS7IHHzd4F6 Ml[yOEBl[Xm| MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRXhHKDV2NlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvOTJizszN NH\KPWwzOjF4OU[wNS=>
PANC1 cells NVnadI1NS3m2b4TvfIlkcXS7IHHzd4F6 M3ziOVQh\GG7cx?= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRW5EOSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;OD6xNkDPxE1? NF[1SYczOjF4OU[wNS=>
22Rv1 cell MnnMR5l1d3SxeHnjbZR6KGG|c3H5 MYW0JIRigXN? NX[3XohbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOjKUdkGgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvODZizszN MX:yNlE3QTZyMR?=
DU145 cells MX;DfZRwfG:6aXPpeJkh[XO|YYm= Mof3OEBl[Xm| M{O1WWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3ME2yMlk6KM7:TR?= MXuyNlE3QTZyMR?=
LNCAP cells M2DJV2N6fG:2b4jpZ4l1gSCjc4PhfS=> NUHySJVTPCCmYYnz MmjLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuOlgh|ryP MWCyNlE3QTZyMR?=
PC3M cells MVjDfZRwfG:6aXPpeJkh[XO|YYm= NU\lSVNJPCCmYYnz MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|NOKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD12LkW1JO69VQ>? MlPyNlIyPjl4MEG=
NIH/3T3 cells MlqzVJJwdGmoZYLheIlwdiCjc4PhfS=> M1nUUFczKGh? MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12LkOg{txO M2PqPVIzPTl3MUe3
NCI-H1648 cell M1m2PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLWd|NKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMEK1OFQh|ryP NYDOWlliW0GQR1XS
NMC-G1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2TEeWlvcGmkaYTpc44hd2ZiaIXtZY4hVk2FLVexJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{42PDVyMTFOwG0> M17sTHNCVkeHUh?=
NTERA-S-cl-D1 cell NX\JR3ppT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2PqW2lvcGmkaYTpc44hd2ZiaIXtZY4hVlSHUlGtV{1kdC2GMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNlY2PjFizszN NEDFeZRUSU6JRWK=
OCUB-M cell MnPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXDSmVKdmirYnn0bY9vKG:oIHj1cYFvKE:FVVKtUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODV5NDFOwG0> NX3IdnFxW0GQR1XS
OS-RC-2 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPUe5ZKdmirYnn0bY9vKG:oIHj1cYFvKE:VLWLDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl7MUm5JO69VQ>? NUnwe41uW0GQR1XS
OVCAR-4 cell M164PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnr6TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4yOTZ5NTFOwG0> NG\iemVUSU6JRWK=
RL95-2 cell Ml7aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkDZTY5pcWKrdHnvckBw\iCqdX3hckBTVDl3LUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE2PjdizszN NHPpXm5USU6JRWK=
SW954 cell M4TGdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M13F[mlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6OjR3IN88US=> NWDoOYRUW0GQR1XS
SW962 cell M{TKNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4i1VGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6OjR3IN88US=> M2\lUXNCVkeHUh?=
TE-1 cell NHPMXGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkCyNVU6KM7:TR?= M{LOOHNCVkeHUh?=
A253 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{nhUWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ3MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFQ5OyEQvF2= MmrwV2FPT0WU
A388 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfSVZFKdmirYnn0bY9vKG:oIHj1cYFvKEF|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA1QDNizszN NFnYSGZUSU6JRWK=
BB30-HNC cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PzN|NTFOwG0> NXLTUnNCW0GQR1XS
TE-12 cell MlzYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLWO5BKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjJ3ODFOwG0> NUjiW4tKW0GQR1XS
TE-5 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK0OlU1KM7:TR?= MYTTRW5ITVJ?
TE-6 cell M{LafWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlXuTY5pcWKrdHnvckBw\iCqdX3hckBVTS14IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60PVA2PyEQvF2= MXnTRW5ITVJ?
TE-8 cell NIjUTWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWfJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkCzO|Mh|ryP NXryS|JCW0GQR1XS
TE-9 cell NVvs[I51T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1NlAyKM7:TR?= M1TaO3NCVkeHUh?=
TK10 cell NYnPU|IyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1n6ZmlvcGmkaYTpc44hd2ZiaIXtZY4hXEtzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVY2OjJizszN M2\TRXNCVkeHUh?=
DSH1 cell NYDYWo1RT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mlj2TY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPVM6PiEQvF2= MYLTRW5ITVJ?
ECC12 cell M4PGXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVvJcohq[mm2aX;uJI9nKGi3bXHuJGVESzF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPVI{OSEQvF2= NXi0PIkyW0GQR1XS
EKVX cell NF7KNZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HlWmlvcGmkaYTpc44hd2ZiaIXtZY4hTUuYWDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFQ5PzRizszN NXnvPZFCW0GQR1XS
HCC2218 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ{MUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA2OzJ4IN88US=> MVTTRW5ITVJ?
LB2241-RCC cell MoDVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIjaU4lKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkG1OFA{KM7:TR?= NY\6fIs{W0GQR1XS
LB996-RCC cell Mo\US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGxDQTl4LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzZ{Mkig{txO NVXYc41jW0GQR1XS
LC-1F cell MoHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzJS4RXUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2xSkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzh{NESg{txO M3zhdnNCVkeHUh?=
LS-513 cell M1fMT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlHMTY5pcWKrdHnvckBw\iCqdX3hckBNWy13MUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQxODRzIN88US=> NESyU25USU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ErbB2 / t-ErbB2 / p-Akt / t-Akt / p-Erk / t-Erk; 

PubMed: 25238247     


Dose response of lapatinib and PD168393 on phosphorylation of ErbB2, AKT and ERK in Calu3 and SkBr3 cells in response to EGF treatment. p-ErbB2: phosphorylated ErbB2; t-ErbB2: total-ErbB2; p-AKT: phosphorylated AKT; t-AKT: total AKT; p-ERK: phosphorylated ERK; t-ERK: total ERK.

pEGFR / EGFR / p-mTOR / mTOR / PARP / c-PARP ; 

PubMed: 28938602     


SKBR3 and 78617 cells were treated with lapatinib as in panel A, then the expression of phospho-ErbB2 (Tyr1221/1222), ErbB2, phospho-EGFR (Tyr1068), EGFR, phospho-Akt (Ser473), Akt, phospho-Erk1/2 (Thr202/Tyr204), Erk2, phospho-mTOR (Ser2448), and mTOR were analyzed using Western blotting. All values are presented as the mean ± standard error (S.E.) (**p < 0.01).

25238247 28938602
Growth inhibition assay
Cell viability ; 

PubMed: 24947784     


Huh7 (A), HepG2 (B), or HA22T (C) HCC cells were left untreated or treated with 0.1% DMSO (vehicle, D) or with DMSO containing various concentrations of lapatinib (1.25, 2.5, 5, or 10 μM) for 3 days. Relative amounts of viable cells were detected by MTS assay. O.D. values from DMSO-treated control cells were designated 100%.

24947784
In vivo Oral administration of Lapatinib Ditosylate (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. [1]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase assays:

The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.
Cell Research:[1]
- Collapse
  • Cell lines: HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells
  • Dosages: ~100 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 925.46
Formula

C29H26ClFN4O4S.2C7H8O3S

CAS No. 388082-77-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04608409 Recruiting Drug: Lapatinib and Paclitaxel Ovarian Cancer Frederick R. Ueland M.D.|University of Kentucky November 16 2020 Phase 1
NCT03075995 Unknown status Other: hight-fat breakfast Breast Cancer Sun Yat-sen University April 12 2017 Not Applicable
NCT02338245 Completed Drug: ASLAN001|Drug: Lapatinib|Drug: Capecitabine Metastatic Breast Cancer Aslan Pharmaceuticals December 29 2014 Phase 2
NCT02294786 Terminated Drug: Lapatinib|Drug: Capecitabine|Drug: Octreotide Cancer Novartis Pharmaceuticals|Novartis December 17 2014 Phase 2
NCT02213042 Completed Drug: Lapatinib|Biological: Trastuzumab Neoplasms Breast Novartis Pharmaceuticals|Novartis October 24 2014 Phase 2
NCT01782651 Completed Drug: Lapatinib plus capecitabine Neoplasms Breast GlaxoSmithKline August 2014 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    If I need to use S1028 for treating tumor-bearing mice with injection, how could I prepare the solution?

  • Answer:

    S1028 Lapatinib Ditosylate can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as clear solution.

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

Related HER2 Products

Tags: buy GW-572016|GW-572016 ic50|GW-572016 price|GW-572016 cost|GW-572016 solubility dmso|GW-572016 purchase|GW-572016 manufacturer|GW-572016 research buy|GW-572016 order|GW-572016 mouse|GW-572016 chemical structure|GW-572016 mw|GW-572016 molecular weight|GW-572016 datasheet|GW-572016 supplier|GW-572016 in vitro|GW-572016 cell line|GW-572016 concentration|GW-572016 nmr|GW-572016 in vivo|GW-572016 clinical trial|GW-572016 inhibitor|GW-572016 Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID